Formulation and Drug Delivery

The final drug product relies on the quality and reliability of the raw materials used in its production.

Biosimilar analytical assessments focus on demonstrating biosimilarity and interchangeability with the reference biologic.

Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.

Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.

Pharm Tech Group chats with Dr. Monika Paulė, CEO and co-founder of Caszyme about the evolution of CRISPR.

A combination of rapid sterility methods with the industry standard compendial method should ensure maximum safety.

Bkemv (eculizumab-aeeb) is the first interchangeable biosimilar to Soliris (eculizumab) to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

In an ASGCT Panel on nucleic acid- and cell-based vaccines in oncology, work on a personalized mRNA vaccine was highlighted.

The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.

Ken Keller, president and CEO, Daiichi Sankyo, discusses the foundation of partnership and takes a look at the future of biotech partnerships at the US Pharma and Biotech Summit.

At CPHI NA, Rachel Harris, AstraZeneca, spoke on her work at BioPhorum to enable industry consensus and action for sustainability with drug delivery devices.

The company’s presentation at ASGCT includes preliminary data results for a child who received the gene therapy.

A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics.

Novel delivery technologies enhance brain penetration to target neurodegenerative diseases and glioblastomas.

The use of appropriate taste-masking and appearance technologies can facilitate patient compliance.

A comparison between polysorbates and HPβCD determines the better stabilizer for biologics formulation.

In this exclusive Drug Digest video interview, Chris Spivey, Director, Industry Relations and Strategic Partnerships, talks with industry experts about various aspects of drug product stability testing.

Technological advances are helping advance biologics development and manufacturing and reduce bottlenecks.

A tidal wave of questions floats the need for more upstream automation.

Developing freeze-drying processes requires patience and deep product and process understanding.

Regulations for mRNA products are evolving as the market for mRNA expands.

The LNP success in mRNA vaccines leads to their establishment as a standard in mRNA delivery.

In this exclusive Drug Digest video interview, Felicity Thomas, Europe/senior editor, Pharmaceutical Technology Group, interviews Dr. Krizia M. Karry, Global Head of Technical Marketing for BASF Pharma Solutions, on the topic of hot melt extrusion.

Advanced oral dosage forms allow for modulation of controlled- and sustained-release profiles.

Packaging and packaging line innovations are addressing the industry’s growing use of biologics.

Dr. Reddy’s has gained exclusive rights to promote and distribute Sanofi’s vaccines in India.

The draft guidance document provides support to sponsors with drugs in clinical development that treat the states of sporadic Alzheimer’s disease.

New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.

Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.